A 63-Year-Old Man with Myelofibrosis : Episode 7
Emerging JAK Inhibitors for Patients With Myelofibrosis
Dr Oh discusses emerging JAK inhibitors in the myelofibrosis treatment landscape, highlighting clinical evidence that supports their use.
EP: 1.Patient Profile: A 63-Year-Old Man with Myelofibrosis
EP: 2.Determining and Addressing Ruxolitinib Failure in Myelofibrosis
EP: 3.Treatment Sequencing in Myelofibrosis
EP: 4.Monitoring Therapeutic Response in Patients With Myelofibrosis
EP: 5.Pacritinib for Patients With Myelofibrosis
EP: 6.Balancing Toxicity Concerns with Achieving Adequate Response in Myelofibrosis
Now Viewing
EP: 7.Emerging JAK Inhibitors for Patients With Myelofibrosis
EP: 8.Perspectives on the Future on Myelofibrosis Treatment
Case: A 63-Year-Old Man with Myelofibrosis
Clinical Presentation:
- A 63-year-old man recently diagnosed with primary MF and initiated on 10 mg BID ruxolitinib.
- PMH: type 2 diabetes, hypercholesteremia, and hypertension, squamous cell carcinoma (SCC)
Follow up and Clinical Workup at 3 Months:
- Exam: night sweats improved.
- Labs: Hb 7.8 g/dL; Plt 80 x 109/L (previously 135k) stabilized.
- Some spleen reduction.
- Patient receives ~1 unit RBC per month.
Follow up and Clinical Workup at 6 Months:
- Patient reports complaints of fatigue and abdominal pain.
- Labs: Plt 55 x 109/L; Hgb 6.8 g/dL
- Patient now receives 2 units RBC per month.
- Experienced recurrence of SCC.
Related Videos
Related Content
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024Article
During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
